Trial · NCT00619229
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart) | Alprostadil | 0.94 | Standard Deviation 1.84 | Lines read in ETDRS chart | |
| Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart) | Placebo | 0.53 | Standard Deviation 1.66 | Lines read in ETDRS chart | |
| The Difference in Visual Acuity Between Measurements Immediately After Intervention and Measurements at Baseline | Alprostadil | 1.29 | Standard Deviation 1.44 | Lines read in ETDRS chart | |
| The Difference in Visual Acuity Between Measurements Immediately After Intervention and Measurements at Baseline | Placebo | 0.38 | Standard Deviation 1.54 | Lines read in ETDRS chart | |
| The Difference in Visual Acuity Between Measurements at 6 Months After Intervention and Measurements at Baseline | Alprostadil | 1.31 | Standard Deviation 1.45 | Lines read in ETDRS chart | |
| The Difference in Visual Acuity Between Measurements at 6 Months After Intervention and Measurements at Baseline | Placebo | 0.29 | Standard Deviation 2.11 | Lines read in ETDRS chart | |
| Progression of the Dry Age-related Macular Degeneration | Alprostadil | Progression in disease | 11 | Participants | |
| Progression of the Dry Age-related Macular Degeneration | Placebo | Progression in disease | 10 | Participants | |
| Progression of the Dry Age-related Macular Degeneration | Alprostadil | Stabilization of disease | 1 | Participants | |
| Progression of the Dry Age-related Macular Degeneration | Placebo | Stabilization of disease | 3 | Participants | |
| Progression of the Dry Age-related Macular Degeneration | Alprostadil | Amelioration of disease | 4 | Participants | |
| Progression of the Dry Age-related Macular Degeneration | Placebo | Amelioration of disease | 4 | Participants | |
| Development of a Wet Age-related Macular Degeneration | Alprostadil | Yes | 0 | Participants | |
| Development of a Wet Age-related Macular Degeneration | Placebo | Yes | 0 | Participants | |
| Development of a Wet Age-related Macular Degeneration | Alprostadil | No | 16 | Participants | |
| Development of a Wet Age-related Macular Degeneration | Placebo | No | 17 | Participants | |
| The Difference in Contrast Sensitivity Between Measurements Immediately After Intervention and Measurements at Baseline | Alprostadil | 0.009 | Standard Deviation 0.282 | Unit on a scale | |
| The Difference in Contrast Sensitivity Between Measurements Immediately After Intervention and Measurements at Baseline | Placebo | 0.018 | Standard Deviation 0.224 | Unit on a scale | |
| The Difference in Contrast Sensitivity Between Measurements at 3 Months After Intervention and Measurements at Baseline | Alprostadil | 0.084 | Standard Deviation 0.205 | Unit on a scale | |
| The Difference in Contrast Sensitivity Between Measurements at 3 Months After Intervention and Measurements at Baseline | Placebo | -0.026 | Standard Deviation 0.324 | Unit on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00619229/results